This 52-week , multicenter , parallel-arm study ( primary end point : 26 weeks ) randomized patients ( 2:2:2:1 ) to dulaglutide 1.5 mg , dulaglutide 0.75 mg , exenatide 10 g , or placebo ( placebo-controlled period : 26 weeks ) .